In addition, multiple studies demonstrate differences in the proportions of classical (CD14+ CD16-), intermediate (CD14+ CD16+), and non-classical monocytes (CD14lo CD16+), with a notable decrease in circulating non-classical monocytes in moderate and severe COVID-19 (9–12). This evidence concerns the gene CD14 and COVID-19.